Posted on February 19, 2012

Brazil’s, CIENCIA  (SCIENCE) has again profiled the Heffter Research Institute, this time focusing on President, and co-founder, Dr. Dave Nichols. The article written by Dr. Cibele Ruas reports on  Dr. Nichols extensive research on psycho-active substances.

The respected financial site, Bloomberg Businessweek,  has released an extremely positive article on the study of  hallucinations. The article features Heffter Board members Dr. Dave Nichols, Dr. Roland Griffiths, Dr. Charles Grob, and Dr. Stephen Ross. The Heffter Research Institute is also prominently mentioned as the source of  funding for “… 70 studies in research journals since 1999.”

The Los Angeles Times on November 29, 2011 featured a very positive survey article on the status of hallucinogenic research and the changing  perceptions concerning these compounds in the medical community.  As the Times states, “Hallucinogens and other street drugs are increasingly being studied for legitimate therapeutic uses, such as helping patients with post-traumatic stress disorder, addiction, chronic pain, depression and even terminal illness.” The research of  Heffter Board members, Dr. Charles Grob and Dr. Roland Griffiths, is prominently featured including  a wonderful photo of Dr. Grob in his perpetually disheveled office. On a side note Times writer,  Melissa Healy, needs commending for using “hallucinogens”  and not succumbing to the ever so problematic “psychedelic.” While the word is appropriate, it does, regrettably, conjure the stigma that has so effectively shut down this research for thirty years.

Two notes of correction:

Dr. Roland Griffiths is not a “psychopharmacologist” but  is Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine.

Dr. Michael P. Bogenschutz is not based at the University of Arizona  in Tucson.  Dr. Bogenschutz  is Professor and Vice Chair for Research and Addictions in the Department of Psychiatry at  the University of New Mexico in Albuquerque.

Please follow the link for the Los Angeles Times article:,0,969113.story


Posted on November 29, 2011

The Heffter Research Institute is honored to present its Lifetime Achievement Award to Dr. Stanislav Grof. The award was presented to Dr. Grof at the Joshua Tree Retreat Center in Joshua Tree, California on September 23, 2011 by Heffter Board Member, Dr. Charles Grob. Dr. Grof is one of the worlds leading experts in psychedelics and hallucinogens in relation to psychiatry and psychology. 

 As he states,  “… the potential significance of LSD and other psychedelics for psychiatry and psychology was comparable to the value the microscope has for biology or the telescope has for astronomy. My later experience with psychedelics only confirmed this initial impression. These substances function as unspecific amplifiers that increase the cathexis (energetic charge) associated with the deep unconscious contents of the psyche and make them available for conscious processing. This unique property of psychedelics makes it possible to study psychological undercurrents that govern our experiences and behaviours to a depth that cannot be matched by any other method and tool available in modern mainstream psychiatry and psychology. In addition, it offers unique opportunities for healing of emotional and psychosomatic disorders, for positive personality transformation, and consciousness evolution.”

Dr. Grof is an inspiration to generations of scientists, who, because of him,  have not let this field of inquiry vanish.

The following are images of Dr. Charles Grob presenting the award and a close-up. Dr. Grof  is on the left.

All of us at Heffter send Stan and Christina Grof our very best wishes!

Germany’s public radio and television broadcaster ARD has just presented a half hour program on hallucinogens.




The program is present by Arndt Reuning.

Featured in the program is Heffter board member Dr. Charles Grob’s ground breaking study on psilocybin’s efficacy in the treatment of  anxiety and depression in terminal cancer patients. Heffter consultant and spokesperson, Mr. Norbert Litzinger, is also interviewed concerning the tragic death of his wife, Pamela Sakuda, who participated in Dr. Grob’s study and greatly benefited from it.

The program is in transcription and audio in German and can be read and  listened to here. The transcript is translatable through Google or other translation applications.  Please click the following title and then click the title with the audio symbol.


ARD is the second largest public broadcaster in the world with a national and international reach. It utilizes every form of electronic communication. For more information please link to: .


Posted on October 7, 2011

Lame puns aside  Alexander Zaitchik extensive article on psychedelics in SALON is a fine overview concerning their history and present medical status. Prominently featured are Heffter researchers, Dr. Stephen Ross, Dr. Roland Griffiths and Dr. Charles Grob.


Heffter board member, Dr. Stephen Ross, has written a profoundly accessible article on the somber topic of dying. Dr. Ross addresses the medical communities’ odd reluctance  in dealing with death and the distress this further inflicts on patients. He discusses “bad death” and “good death” in relation to  health care and the dying. Spirituality and religion are integrated in his discourse. Most importantly solutions are presented. The article can be viewed in its entirety in the  current journal of  IONS (INSTITUTE OF NOETIC SCIENCES).

For more information on IONS please visit their site:

Dr. Roland Griffiths, Heffter board member, at the Johns Hopkins University School of Medicine is the subject of two articles on the long lasting positive affects of psilocybin on personality. Dr. Griffiths study was also published in The Journal of Psychopharmacology. He is, currently, leading two studies on anxiety reduction in cancer patients and smoking cessation therapy with the use of psilocybin. These studies are supported in part by the Heffter Research Institute .

The articles can be viewed at:


The PSILOCYBIN CANCER ANXIETY STUDY at NYU under the direction of Heffter board member Dr. Stephen Ross has launched their new web site.

They are looking for volunteers to participate in a scientific study exploring the effects of spiritual or mystical states of consciousness on anxiety and emotional distress associated with a diagnosis of advanced, recurrent, or potentially life threatening cancer.

For further information please visit:

The study was conducted by Dr. Roland Griffiths and his co-researchers at the Johns Hopkins University School of Medicine. Please read and ponder the implications of this fascinating study and its conclusions at the following link.

Dr. Griffiths is currently engaged in a Psilocybin study designed to ameliorate the symptoms of anxiety and depression in those facing a diagnosis of life threatening cancer. The study is open and actively recruiting patients.